The domain of cytotoxic drugs used in the treatment of cancer is going to be dominated by the new era of the therapies in the treatment of cancer, which includes targeted treatments like the cancer immunotherapy. One specific and the best advantage of such targeted therapies is that they are specific to the tumors only and do not harm normal or healthy cells, like that of the chemotherapy. As we discuss about the side effects of these conventional treatments, one can say that due to their harsh effects on the healthy cells, they are associated with severe side effects. The quality of living of the patient is affected. Immunotherapy comes as their savior.

If we compare the long lasting effects of these therapies to the conventional drug treatments, the immunotherapeutic drugs provide a long lasting effect, even after the completion or discontinuation of the therapy. This suggests that the immune response against the tumor is developed over time and is long-lasting.

Global Allied Pharmaceuticals (GAP) uses its expertise in the field of immunotherapy to determine effective therapeutic regimens for the treatment of various therapies. Now, GAP is moving ahead with the use of combination therapies to develop a newer treatment regimen. The researchers, at GAP work to identify the effective combinations and prepare a regimen for the same. This helps to break the resistance of the tumor against the immune response.

GAP has effectively developed a combination of the vaccines that are anticancer in nature along with the drugs that prevent the inhibition, so initiated by the tumor over the immune system. A high response rate of up to 50% has been observed, which is quite appreciable. This can give a tough competition to the other treatment strategies that have been developed so far. Even the complete response has also been seen in some of the patients. No sign of cancer has been seen for a considerable period of time.

It has also been observed that the response rate improves over the period of time. This is due to the fact that the immune system targets and kills the tumor cells after a long term of completion of therapy. The drugs that can be used in combination can be the checkpoint inhibitors or the ones that act on the stem cells. We can get a synergistic effect when such combinations are developed that will act complementary to each other.

Along with this, no side effects are associated with immune-system based therapies. Rarely, the side effects develop like fatigue or nausea.

Looking into all these positive developments, one can say that immune-oncology is going to be the market worth multi-billion dollars. A lot of attention has been drawn by these immune-combination strategies. The success stories of these agents, has provided a motivation to several others to work further in this field. With the increase in the knowledge about cellular and molecular basis of the tumors, a number of new pathways have opened to utilize the immune system in the treatment of cancer. The adaptability and durability of immunotherapy helps to offer the treatment in almost all forms of cancer.

Contact us:

160 Vista Oak Dr.

Longwood, FL 32779

Telephone: 321-445-1969

Email id : info@gapsos.com